371 related articles for article (PubMed ID: 33884374)
21. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia.
Cui J; Chen X; Li C; Yan Q; Yuan G
Hematology; 2024 Dec; 29(1):2293512. PubMed ID: 38095287
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
Pollyea DA; Winters A; McMahon C; Schwartz M; Jordan CT; Rabinovitch R; Abbott D; Smith CA; Gutman JA
Bone Marrow Transplant; 2022 Feb; 57(2):160-166. PubMed ID: 34645926
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
[TBL] [Abstract][Full Text] [Related]
25. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
[TBL] [Abstract][Full Text] [Related]
26. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
Hoang DH; Buettner R; Valerio M; Ghoda L; Zhang B; Kuo YH; Rosen ST; Burnett J; Marcucci G; Pullarkat V; Nguyen LXT
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743010
[TBL] [Abstract][Full Text] [Related]
27. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Lane AA; Garcia JS; Raulston EG; Garzon JL; Galinsky I; Baxter EW; Leonard R; DeAngelo DJ; Luskin MR; Reilly CR; Stahl M; Stone RM; Vedula RS; Wadleigh MM; Winer ES; Mughal T; Brooks C; Gupta IV; Stevenson KE; Neuberg DS; Ren S; Keating J; Konopleva M; Stein A; Pemmaraju N
Blood Adv; 2024 Feb; 8(3):591-602. PubMed ID: 38052038
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
[TBL] [Abstract][Full Text] [Related]
29. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
30. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
Forsberg M; Konopleva M
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
Wang N; He J; Liu F
Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
[TBL] [Abstract][Full Text] [Related]
32. [Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
Kunisada K; Matsuoka A; Yoshida S; Taoka T
Rinsho Ketsueki; 2022; 63(12):1621-1625. PubMed ID: 36653133
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM; Pollyea DA; Borate U; Vasconcelos A; Potluri R; Rotter D; Kiendrebeogo Z; Gaugler L; Prebet T; Strocchia M; Bonifacio G; Chen C
Ann Hematol; 2023 Apr; 102(4):749-754. PubMed ID: 36732419
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
Bosc C; Saland E; Bousard A; Gadaud N; Sabatier M; Cognet G; Farge T; Boet E; Gotanègre M; Aroua N; Mouchel PL; Polley N; Larrue C; Kaphan E; Picard M; Sahal A; Jarrou L; Tosolini M; Rambow F; Cabon F; Nicot N; Poillet-Perez L; Wang Y; Su X; Fovez Q; Kluza J; Argüello RJ; Mazzotti C; Avet-Loiseau H; Vergez F; Tamburini J; Fournié JJ; Tiong IS; Wei AH; Kaoma T; Marine JC; Récher C; Stuani L; Joffre C; Sarry JE
Nat Cancer; 2021 Nov; 2(11):1204-1223. PubMed ID: 35122057
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
[TBL] [Abstract][Full Text] [Related]
36. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
37. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
Hurrish KH; Su Y; Patel S; Ramage CL; Zhao J; Temby BR; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
Biochem Pharmacol; 2024 Feb; 220():115981. PubMed ID: 38081370
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
39. Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2.
Culp-Hill R; Stevens BM; Jones CL; Pei S; Dzieciatkowska M; Minhajuddin M; Jordan CT; D'Alessandro A
Metabolites; 2023 Mar; 13(4):. PubMed ID: 37110126
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution.
Drozd-Sokołowska J; Mądry K; Barankiewicz J; Kobylińska K; Biecek P; Rytel J; Karakulska-Prystupiuk E; Skwierawska K; Salomon-Perzyński A; Stokłosa T; Basak GW
Chemotherapy; 2023; 68(1):16-22. PubMed ID: 36103840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
